$CMPX
Compass Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000117184322005187 Filed on August 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.807M $3.125M $2.767M
YoY Change 3.96% 44.28% 5.01%
% of Gross Profit
Research & Development $9.791M $5.862M $4.415M
YoY Change 210.43% 101.79% -6.14%
% of Gross Profit
Depreciation & Amortization $200.0K $220.0K $200.0K
YoY Change 100.0% 120.0% 0.0%
% of Gross Profit
Operating Expenses $12.60M $8.987M $7.182M
YoY Change 115.2% -83.86% -2.14%
Operating Profit -$12.60M -$8.987M -$7.182M
YoY Change 115.2% -83.86% -2.14%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $623.0K $493.0K $20.00K
YoY Change -614.88% -583.33% -124.1%
Pretax Income -$11.98M -$8.494M -$7.162M
YoY Change 100.42% -84.78% -3.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.98M -$8.494M -$7.162M
YoY Change 100.42% -84.78% -3.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.08 -$0.07
Diluted Earnings Per Share -$118.6K -$84.14K -$71.01K
COMMON SHARES
Basic Shares Outstanding 101.3M 100.9M 101.3M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $120.6M $132.0M $136.4M
YoY Change 372.78% 323.03% 243.57%
Cash & Equivalents $16.48M $26.24M $136.4M
Short-Term Investments $104.1M $105.8M
Other Short-Term Assets $1.952M $2.527M $3.904M
YoY Change -36.27% -24.02% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $122.6M $134.5M $140.3M
YoY Change 328.93% 289.6% 236.84%
LONG-TERM ASSETS
Property, Plant & Equipment $1.708M $1.850M $2.142M
YoY Change 19.02% 57.05% -64.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $320.0K $320.0K
YoY Change 0.0% 0.0% -32.06%
Total Long-Term Assets $5.284M $5.711M $6.281M
YoY Change -16.48% -9.89% -4.12%
TOTAL ASSETS
Total Short-Term Assets $122.6M $134.5M $140.3M
Total Long-Term Assets $5.284M $5.711M $6.281M
Total Assets $127.8M $140.3M $146.6M
YoY Change 266.31% 243.16% 204.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.761M $6.532M $257.0K
YoY Change 218.09% 1068.52% -75.78%
Accrued Expenses $5.742M $3.301M $8.050M
YoY Change 187.39% 181.18% 524.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.578M $10.88M $9.334M
YoY Change 24.66% 29.68% -13.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.144M $2.444M $2.740M
YoY Change -35.58% -32.19% -29.33%
Total Long-Term Liabilities $2.144M $2.444M $2.740M
YoY Change -29.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.578M $10.88M $9.334M
Total Long-Term Liabilities $2.144M $2.444M $2.740M
Total Liabilities $11.72M $13.33M $12.07M
YoY Change 6.46% 11.09% -18.01%
SHAREHOLDERS EQUITY
Retained Earnings -$261.2M -$249.2M -$240.8M
YoY Change 18.41% 16.13%
Common Stock $378.0M $376.7M $375.2M
YoY Change 54.59% 54.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $116.1M $126.9M $134.5M
YoY Change
Total Liabilities & Shareholders Equity $127.8M $140.3M $146.6M
YoY Change 266.31% 243.16% 204.09%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$11.98M -$8.494M -$7.162M
YoY Change 100.42% -84.78% -3.5%
Depreciation, Depletion And Amortization $200.0K $220.0K $200.0K
YoY Change 100.0% 120.0% 0.0%
Cash From Operating Activities -$10.94M -$4.600M -$7.942M
YoY Change 216.52% -22.55% 41.69%
INVESTING ACTIVITIES
Capital Expenditures -$27.00K $63.00K $194.0K
YoY Change -92.64% -110.26% 51.56%
Acquisitions
YoY Change
Other Investing Activities $1.207M -$105.6M $1.000K
YoY Change -99.13%
Cash From Investing Activities $1.180M -$105.5M -$193.0K
YoY Change -421.53% 17089.09% 1384.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 0.000 0.000
YoY Change -100.27% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -10.94M -4.600M -7.942M
Cash From Investing Activities 1.180M -105.5M -193.0K
Cash From Financing Activities 5.000K 0.000 0.000
Net Change In Cash -9.757M -110.1M -8.135M
YoY Change 71.21% 1206.85% 8.57%
FREE CASH FLOW
Cash From Operating Activities -$10.94M -$4.600M -$7.942M
Capital Expenditures -$27.00K $63.00K $194.0K
Free Cash Flow -$10.92M -$4.663M -$8.136M
YoY Change 253.24% -12.43% 41.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101284000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101303000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100968000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100832000
CY2022Q2 cmpx Number Of Operating Leases
NumberOfOperatingLeases
1 pure
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M1D
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P35Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31418000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity File Number
EntityFileNumber
001-39696
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4876496
dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest St., Suite 601
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
500-8099
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CMPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101284613
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26238000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144514000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6532000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
105780000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2527000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2591000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
134545000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
147105000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1850000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3541000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4089000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 usd
CY2022Q2 us-gaap Assets
Assets
140256000 usd
CY2021Q4 us-gaap Assets
Assets
153757000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
867000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3301000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1051000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
989000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10884000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10631000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2444000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3048000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
13328000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
13679000 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
376675000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373657000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-512000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249245000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233589000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
126928000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140256000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153757000 usd
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5862000 usd
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2905000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10278000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7609000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3125000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2166000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5891000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4798000 usd
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8987000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
55689000 usd
us-gaap Operating Expenses
OperatingExpenses
16169000 usd
us-gaap Operating Expenses
OperatingExpenses
63025000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8987000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55689000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16169000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-63025000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
513000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8494000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55791000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15656000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63210000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8494000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55804000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15656000 usd
us-gaap Net Income Loss
NetIncomeLoss
-63223000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100947000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51913000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100903000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51582000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8494000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55804000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15656000 usd
us-gaap Net Income Loss
NetIncomeLoss
-63223000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-512000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-512000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9006000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55804000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16168000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63223000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1574000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7162000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
134490000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1444000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-512000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8494000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
126928000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
948000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7422000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33471000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
50300000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55804000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
28875000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15656000 usd
us-gaap Net Income Loss
NetIncomeLoss
-63223000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
385000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
304000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
70000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
22000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3018000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1856000 usd
cmpx Marketable Securities Amortization Of Premium And Discount
MarketableSecuritiesAmortizationOfPremiumAndDiscount
110000 usd
cmpx Marketable Securities Amortization Of Premium And Discount
MarketableSecuritiesAmortizationOfPremiumAndDiscount
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
548000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
518000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-64000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
200000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5588000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-502000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5987000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-398000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-542000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-495000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12542000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11544000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
424000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
105779000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
-0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
318000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
176000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105734000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-627000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
-0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
3750000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3750000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-118276000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15921000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144514000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26238000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
512000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105780000 usd
us-gaap Interest Paid Net
InterestPaidNet
226000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5148000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
512000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0 usd
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
50300000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
77000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
cmpx Purchase Of Securities Included In Accrued Expenses
PurchaseOfSecuritiesIncludedInAccruedExpenses
513000 usd
cmpx Purchase Of Securities Included In Accrued Expenses
PurchaseOfSecuritiesIncludedInAccruedExpenses
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
329000000.0 usd
CY2022Q2 cmpx Cash And Marketable Securities
CashAndMarketableSecurities
132000000.0 usd
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625 pure
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106292000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1444000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
948000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3018000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1856000 usd
CY2021Q4 cmpx Accrued Project Expenses Current
AccruedProjectExpensesCurrent
704000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12600000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.95
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
88480000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
17300000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105780000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7021000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7269000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5171000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5026000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1850000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000 usd
us-gaap Depreciation
Depreciation
400000 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2182
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
845000 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1601000 usd
CY2022Q2 cmpx Accrued Project Expenses Current
AccruedProjectExpensesCurrent
1651000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M14D
CY2022Q2 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
0 usd
CY2021Q4 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
6000000 usd
CY2022Q2 cmpx Marketable Securities Not Settlement Current
MarketableSecuritiesNotSettlementCurrent
513000 usd
CY2021Q4 cmpx Marketable Securities Not Settlement Current
MarketableSecuritiesNotSettlementCurrent
0 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
292000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
470000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3301000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
550000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1345000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1379000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
543000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3817000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
322000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3495000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1051000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2444000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
47000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
47000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8200000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3659
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.99
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2229
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.29
cmpx Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y6M10D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
244
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.06
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5644
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M8D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
839000 usd
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0193 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0076 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.903 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.893 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
424000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
443000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
-0 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
111000 usd
us-gaap Interest Expense
InterestExpense
-0 usd
us-gaap Interest Expense
InterestExpense
253000 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
69000 usd
CY2021Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
70000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
513000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185000 usd

Files In Submission

Name View Source Status
0001171843-22-005187-index-headers.html Edgar Link pending
0001171843-22-005187-index.html Edgar Link pending
0001171843-22-005187.txt Edgar Link pending
0001171843-22-005187-xbrl.zip Edgar Link pending
cmpx-20220630.xsd Edgar Link pending
cmpx-20220630_cal.xml Edgar Link unprocessable
cmpx-20220630_def.xml Edgar Link unprocessable
cmpx-20220630_lab.xml Edgar Link unprocessable
cmpx-20220630_pre.xml Edgar Link unprocessable
cmpx20220630_10q.htm Edgar Link pending
cmpx20220630_10q_htm.xml Edgar Link completed
compasslogo.jpg Edgar Link pending
ctxschema.jpg Edgar Link pending
duration.jpg Edgar Link pending
ex_397305.htm Edgar Link pending
ex_397306.htm Edgar Link pending
ex_397307.htm Edgar Link pending
ex_397308.htm Edgar Link pending
ex_398690.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tumordecline.jpg Edgar Link pending